TY  - GEN
AB  - Plasma cell neoplasms are a spectrum of disorders caused by the proliferation of monoclonal plasma cells in the bone marrow leading to the production of monoclonal immunoglobulin. Included in this spectrum, from least severe to most severe, are monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and plasma cell myeloma. Each diagnosis carries a different prognosis and requires different clinical management. For example, the median overall survival of patients with Stage I, II, and III PCM has been shown to be 62, 44, and 29 months, respectively, while the median overall survival of patients with monoclonal gammopathy of undetermined significance is expected to be only slightly shorter than that of age-matched controls.1-4 Thus, making the correct diagnosis amongst this spectrum of disorders is paramount for the prognostication and proper clinical management of plasma cell neoplasms.
AD  - Oregon Health and Science University
AU  - Ngoc, Tran
DA  - 2020
DO  - 10.6083/w3763753n
DO  - DOI
ID  - 8043
KW  - Bone Marrow
KW  - Algorithms
KW  - computer assisted image analysis
KW  - plasma cell neoplasms
KW  - cd138 antigen
L1  - https://digitalcollections.ohsu.edu/record/8043/files/Ngoc.Tran.2020.pdf
L2  - https://digitalcollections.ohsu.edu/record/8043/files/Ngoc.Tran.2020.pdf
L4  - https://digitalcollections.ohsu.edu/record/8043/files/Ngoc.Tran.2020.pdf
LK  - https://digitalcollections.ohsu.edu/record/8043/files/Ngoc.Tran.2020.pdf
N2  - Plasma cell neoplasms are a spectrum of disorders caused by the proliferation of monoclonal plasma cells in the bone marrow leading to the production of monoclonal immunoglobulin. Included in this spectrum, from least severe to most severe, are monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and plasma cell myeloma. Each diagnosis carries a different prognosis and requires different clinical management. For example, the median overall survival of patients with Stage I, II, and III PCM has been shown to be 62, 44, and 29 months, respectively, while the median overall survival of patients with monoclonal gammopathy of undetermined significance is expected to be only slightly shorter than that of age-matched controls.1-4 Thus, making the correct diagnosis amongst this spectrum of disorders is paramount for the prognostication and proper clinical management of plasma cell neoplasms.
PB  - Oregon Health and Science University
PY  - 2020
T1  - Validation of an image analysis algorithm for quantifying CD138 immunohistochemical marker in  plasma cell neoplasms
TI  - Validation of an image analysis algorithm for quantifying CD138 immunohistochemical marker in  plasma cell neoplasms
UR  - https://digitalcollections.ohsu.edu/record/8043/files/Ngoc.Tran.2020.pdf
Y1  - 2020
ER  -